| Gene symbol | BCL2 | Synonyms | Bcl-2, PPP1R50 | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | BCL2 apoptosis regulator | ||||
| GTO ID | GTC1212 |
| Trial ID | NCT00070343 |
| Disease | Melanoma |
| Altered gene | Bcl-2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Genasense|G3139|oblimersen sodium |
| Co-treatment | dacarbazine |
| Recruitment status | Unknown |
| Title | Continuation Protocol For G3139 (Bcl-2 Antisense Oligonucleotide) And Dacarbazine In Patients With Malignant Melanoma Who Responded To This Combination In Protocol GM301 |
| Year | 2003 |
| Country | United States |
| Company sponsor | Jonsson Comprehensive Cancer Center |
| Other ID(s) | CDR0000331927|UCLA-0307016|GENTA-GM214 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||